Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

20122,012 citationsJournal Articlebronze Open Access

Authors

Gregory G. Schwartz · Denver VA Medical Center

Anders Olsson · Linköping University

Markus Abt · Roche (Switzerland)

Christie M. Ballantyne · Baylor College of Medicine

Philip J. Barter · The Heart Research Institute

Jochen Brumm · Roche (Switzerland)

Bernard Chaitman ·

Abstract

In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).

Topics & Keywords

Cardiac Imaging and Diagnostics Lipoproteins and Cardiovascular Health Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 367, Issue 22, pp. 2089-2099

DOI: 10.1056/nejmoa1206797

Field-Weighted Citation Impact: 158.15